Skip to main content

MoneyWorks4Me

Ajanta Pharma informs about disclosure of material impact of COVID-19

11 Jun 2020 Evaluate

Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI circular No. SEBI/HO/CFD/CMDl/CIR/P/2020/84 dated 20th May 2020, Ajanta Pharma has informed that it has enclosed the disclosure of material impact of COVID 19 pandemic on listed companies.

The above information is a part of company’s filings submitted to BSE.


Peers
Company Name CMP
Sun Pharma. Inds. 1763.30
Dr. Reddys Labs. 1347.20
Cipla 1366.10
Lupin 1987.40
Zydus Lifesciences 1180.80
View more..